Related to FSD Drugs Advance as Women Push for Equal Access

• FDA Approves AdvanDx’ Faster PNA FISH Protocol for Identifying Enterococcal Bloodstream Pathogens
  
• FDA Grants Emergency Use Authorization to Gen-Probe's PCR Test for the H1N1 Flu
  
• FDA Sanctions Gloucester Pharmaceuticals’ Cutaneous T-Cell Lymphoma Therapy
  
• FDA Okays Dyax’ Subcutaneous Kallikrein Inhibitor for Acute HAE
  
• AstraZeneca’s Antidepressant Gets FDA Nod for Label Expansion
  
• FDA Approves First Generic Version of Pfizer and Eisai’s Alzheimer Drug
  
• FDA Clears Roche/Chugai’s mAb for Rheumatoid Arthritis
  
• Acorda Obtains FDA Nod for Oral Drug that Improves Walking in MS Patients
  
• Novo Nordisk’s Type 2 Diabetes Drug Green-Lighted by FDA
  
• Auxilium’s Dupuytren Contracture Therapy Green-Lighted by FDA
  
• FDA Asks IntelGenx to Fine-Tune CMO and Food Effect Details for Antidepressant Approval
  
• ReNeuron Raises £4.7M to Fund Phase I Study with Stem Cell Therapy for Ischemic Stroke
  
• NIH and FDA Join Forces to Advance Translational Medicine and Regulatory Science
  
• Shire’s Gaucher Disease Therapy Gets FDA Green Light
  
• BMS’ Transplant-Rejection Drug Passes FDA’s Advisory Panel
  
• FDA Sanctions CSL Behring’s Subcutaneous Immunoglobulin Therapy
  
• Enzo to Market MultiGEN’s Sequencing-Based Women’s Health Tests in New York State
  
• FDA Stalls Approval of Amylin, Lilly, and Alkermes’ Type 2 Diabetes Therapy
  
• Recordati Reports U.S. Sanction of Treatment for Hyperammonemia due to NAGS Deficiency
  
• FDA Not Ready to Approve A.P. Pharma’s Treatment for Chemotherapy-Induced Nausea and Vomiting